Merrimack Pharmaceuticals, Inc.
MACK
MACK was delisted on the 17th of May, 2024.
67 hedge funds and large institutions have $125M invested in Merrimack Pharmaceuticals, Inc. in 2023 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 24 increasing their positions, 11 reducing their positions, and 7 closing their positions.
118% more repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 11
77% more call options, than puts
Call options by funds: $3.67M | Put options by funds: $2.07M
57% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 7
20% more capital invested
Capital invested by funds: $104M → $125M (+$20.4M)
6% more funds holding
Funds holding: 63 → 67 (+4)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WSL
Western Standard LLC
Los Angeles,
California
|
+$3.52M |
| 2 |
ICM
Indaba Capital Management
San Francisco,
California
|
+$1.1M |
| 3 |
BlackRock
New York
|
+$667K |
| 4 |
Renaissance Technologies
New York
|
+$618K |
| 5 |
Two Sigma Investments
New York
|
+$276K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CC
Centiva Capital
New York
|
-$2.32M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$961K |
| 3 |
KCM
Kennedy Capital Management
St Louis,
Missouri
|
-$600K |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
-$166K |
| 5 |
FLC
Fifth Lane Capital
Austin,
Texas
|
-$134K |
MACK Hedge Fund Activity: Q4 2023 in Review
67 of the 6,869 institutional investors tracked by Wall St. Rank reported a position in Merrimack Pharmaceuticals, Inc. (MACK) for Q4 2023, worth a combined $125M — up 20% from $104M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new MACK positions and 7 closed out — a net gain of 4 holders — while 24 added to existing stakes and 11 trimmed.
The largest buyer was Western Standard LLC, adding an estimated $3.52M. The largest seller was Centiva Capital, exiting entirely with an estimated $2.32M sold.
- 67 institutional investors held Merrimack Pharmaceuticals, Inc. (MACK) as of Q4 2023, up from 63 in Q3 2023.
- Funds reported $125M of Merrimack Pharmaceuticals, Inc. stock for Q4 2023, up 20% quarter-over-quarter.
- 11 funds opened new Merrimack Pharmaceuticals, Inc. positions in Q4 2023 and 7 closed out, a net change of +4 holders.
- The largest Merrimack Pharmaceuticals, Inc. buyer in Q4 2023 was Western Standard LLC, an estimated $3.52M added.
- The largest Merrimack Pharmaceuticals, Inc. seller in Q4 2023 was Centiva Capital, an estimated $2.32M sold.
Based on aggregated 13F filings for Q4 2023.